| Market Capitalization (Millions $) |
1,474 |
| Shares
Outstanding (Millions) |
55 |
| Employees |
45 |
| Revenues (TTM) (Millions $) |
56 |
| Net Income (TTM) (Millions $) |
-185 |
| Cash Flow (TTM) (Millions $) |
46 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Kalvista Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of small molecule protease inhibitors for the treatment of serious orphan and rare diseases. The company's primary focus is on creating innovative therapies for diseases affecting the eyes, such as hereditary angioedema and diabetic macular edema.
Kalvista's drug candidates are designed to target proteases, which are enzymes that play a role in various diseases by causing excessive vascular permeability and inflammation. By inhibiting these proteases, Kalvista aims to reduce the symptoms and progression of these diseases.
The company utilizes its proprietary drug discovery platform to identify and develop new drug candidates. This platform combines structural biology, medicinal chemistry, and drug development expertise to rapidly advance molecules from discovery through preclinical and clinical development.
Kalvista Pharmaceuticals Inc is based in the United States and collaborates with academic institutions, healthcare organizations, and other pharmaceutical companies to accelerate the advancement of its therapies. The company is committed to improving the lives of patients suffering from rare and orphan diseases through innovative treatments.
Company Address: 200 Crossing Boulevard Framingham 1702 MA
Company Phone Number: 999-0075 Stock Exchange / Ticker: NASDAQ KALV
|
%
2.13% 
95.84 %